driving to work yesterday, there was some coverage on the news of a Chinese preventative medical development for COVIS strains by CanSino Biologics. This is currently being trialed for approvals in China initially. The broadcast also went on to say that once completed, they would then focus on a nasal application as this is deemed to be more effective than the inhaler method.
I took this as a positive for Nasodine as they are not as advanced on the Inhaler then move towards a nasal solution which would have them trailing FRE by more than a year.
Although this is not directly in competition with FRE as the initial application is for the common cold, however i do seem to remember that Nasodine had trials and approval in Africa for COVID and SARS?
Would be interested to hear your thoughts on this.
Andy
FRE Price at posting:
32.0¢ Sentiment: Hold Disclosure: Held
